BIO-SCALE Act
- Sponsor
- Rep. Baird, James R. [R-IN-4]
- Committees
- Financial Services Committee (primary)
- Last action
- May 20, 2026
Bottom line
The BIO-SCALE Act aims to boost U.S. leadership in bioindustrial innovation by funding and establishing critical infrastructure for scaling up bio-based product development, thereby enhancing national security and economic growth.
What it actually does
This bill establishes a program within the Department of Commerce to create at least three regional, nonprofit, open-access, product-agnostic technology maturation facilities for the bioindustrial sector. These facilities are designed to provide world-class infrastructure for the development, testing, and scaling of bio-based technologies, accelerating their commercialization and integration into industrial processes.
Proponents argue
Proponents argue that the bill is crucial for national security and economic competitiveness, as it addresses a critical gap in infrastructure for scaling bioindustrial technologies. They contend it will accelerate commercialization, create jobs, and reduce reliance on foreign supply chains for bio-based products, positioning the U.S. as a global leader in this strategic sector.
Opponents contend
Opponents might argue that the program represents unnecessary government intervention in a sector that private industry should primarily fund, potentially leading to market distortions or inefficient allocation of resources. Concerns could also be raised regarding the scale of federal spending or the potential for political influence in facility selection.
The bill is concise and clearly structured, allowing for a thorough understanding within a reasonable timeframe, making it accessible for evaluation by an informed reader.
Section 1
Short Title
This section formally names the Act as the "Bioindustrial Infrastructure for Open Scale-up, Commercialization, and Accelerated Launch Ecosystems Act" or the "BIO-SCALE Act." This provides a recognizable and concise name for the legislation, facilitating its reference and discussion.
Supporters argue
Supporters argue that a clear and memorable short title helps in public discourse and legislative tracking, making the bill's purpose more accessible and identifiable.
Critics contend
No specific opposition is typically raised against short titles, as they are standard legislative practice.
Tradeoffs
None apparent for this provision.
Section 2(c)
Establishment of Regional Technology Maturation Facilities
This provision directs the Secretary of Commerce to establish at least three regional, nonprofit, open-access, product-agnostic technology maturation facilities for the bioindustrial sector. These facilities are intended to integrate advanced capabilities like various fermentation methods and scalable commercial-grade fermentation tanks (ranging from 1,500 to over 75,000 liters capacity) to support the development, testing, and scaling of bioindustrial technologies.
Section 2(d) and (e)
Secretary's Implementation Plan and Facility Selection
The Secretary of Commerce must submit an implementation plan within 180 days, detailing site selection criteria, funding methodologies, design specifications, and an outreach strategy. Within one year, the Secretary must solicit proposals and select at least three facilities, prioritizing geographical distribution, proximity to feedstock sources, established bioindustrial capabilities, and demonstrated regional need (especially rural areas).
Section 2(f)
Funding Allocation and Expenditure Deadlines
Funds provided for facilities are designated for construction, equipment procurement, and initial operating expenses. The bill sets deadlines for expending these funds: 2 years for facilities with existing infrastructure and 3 years for newly constructed facilities, starting from the date amounts were provided to the facility.
Section 2(g)
Operational Goals for Facilities
This section outlines the primary objectives for the established facilities, including advancing bioindustrial innovation, strengthening national security by de-risking biotechnologies, enhancing U.S. leadership in biotechnology, establishing secure digital infrastructure for data sharing, and providing unique technical capabilities to boost economic growth and international competitiveness.
Section 2(h)
Oversight, Partnerships, and Coordination
The Secretary is mandated to oversee facility design and construction, establish partnerships with industry, academia, and other federal agencies (e.g., DOE, DOD, USDA, DOT, NSF), develop policies for equitable and open access (including rural communities), pursue cost-sharing with private stakeholders, and coordinate with various stakeholders to identify suitable locations and capabilities.
Section 2(i)
Intellectual Property and Data Sharing
Intellectual property created by federal employees at a facility is considered part of the public domain. IP created by non-federal individuals is protected under applicable intellectual property laws, subject to agreements with the Secretary. Facilities must also establish secure, interoperable digital systems to facilitate data exchange across government, academia, and industry.
Section 2(k)
Funding Authorization
The bill authorizes $345,000,000 for fiscal years 2026-2028 and $117,000,000 for fiscal years 2029-2030 to carry out the program. Up to 7.5% of these authorized amounts can be used for administrative and oversight costs by the Secretary of Commerce.
The facilities established under this Act must be "open access" (available without licensing or intellectual property barriers, and accessible equitably to public and private entities) and "product-agnostic" (capable of accommodating a variety of end products without being limited to a specific output).
Section 2(a)(5), (6) and 2(c)(1)
Why it matters:This is standard legislative practice to define key terms upfront for clarity and consistent application throughout the bill, rather than being an attempt to obscure the provisions.
Case for: Proponents argue that open access and product-agnostic design maximize the utility of public investment, ensuring broad participation, fostering diverse innovation, and preventing the facilities from becoming captive to specific commercial interests. This democratizes access to expensive infrastructure, particularly benefiting small and medium-sized enterprises (SMEs) and startups.
Case against: Some private sector entities might find the 'open access' requirement challenging, particularly regarding the sharing of proprietary processes or data, even with the bill's provisions for protecting non-federal intellectual property. They might prefer more exclusive access for their specific research and development, potentially limiting their engagement.
Estimated impact: This requirement fundamentally shapes the operational model of the facilities, influencing who uses them, what types of projects are undertaken, and the overall impact on the bioindustrial ecosystem. It aims for broad public benefit and widespread innovation.